HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

BENEFITS OF NOLODATAK IN DORSALGIAS

DOI: https://doi.org/10.29296/25877305-2018-05-06
Download full text PDF
Issue: 
5
Year: 
2018

T. Potupchik, Candidate of Medical Sciences; O. Veselova, Candidate of Medical Sciences Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

The paper gives data on the benefits of Nolodatak (flupirtine) versus to non-steroidal anti-inflammatory drugs for dorsalgias.

Keywords: 
pharmacology
neurology
therapy
flupirtine
Nolodatak
nonsteroidal anti-inflammatory drugs
dorsalgias
gastropathy



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Anan'eva L.P., Podchufarova E.V. Sovremennye protivobolevye sredstva v apteke / M.: MTsFER, 2005; 158 s.
  2. Vahnina N.V. Hronicheskaja pojasnichno-kresttsovaja bol': diagnostika i lechenie // Nevrol., psihiat., psihosomat. – 2010; 3: 30–4.
  3. Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. Primenenie katadolona u bol'nyh so spondilogennoj dorsopatiej // Zhurn. nevrol. i psihiatr. – 2006; 106 (11): 46–9.
  4. Kamchatnov P.R., Radysh B.B., Kutenev A.V. i dr. Bol' v nizhnej chasti spiny – sovremennye vozmozhnosti terapevticheskoj taktiki // Trudnyj patsient. – 2009; 10 (7): 9–12.
  5. Karateev A.E., Nasonova V.A. Rasprostranennost', struktura i faktory riska razvitija gastropatij, indutsirovannyh nesteroidnymi protivovospalitel'nymi preparatami // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2000; 4: 15–7.
  6. Karateev A.E., Nasonov E.L., Koreshkov G.G. NPVP-indutsirovannaja dispepsija: rasprostranennost' i vozmozhnost' medikamentoznoj korrektsii // Nauch.-prakt. revmatol. – 2003; 5: 76–8.
  7. Kotova O.V., Akarachkova E.S. Mesto preparata nolodatak v lechenii boli v spine // Farmateka. – 2015; 13: 70–3.
  8. Kukushkin M.L. Nespetsificheskaja bol' v nizhnej chasti spiny. Diagnostika, lechenie, preduprezhdenie / M., 2008; 70 s.
  9. Magomedova M., Kamchatnov P. Effektivnost' i bezopasnost' lechenija patsientov s pojasnichnoj bol'ju // Vrach. – 2016; 3: 29–32.
  10. Murav'ev Ju.V., Alekseeva A.V., Tsapina T.N. Vsegda li terapija «bezopasnymi» NPVP bezopasna dlja slizistoj obolochki zheludochno-kishechnogo trakta? // Ros. gastroenterol. zhurn. – 2002; 2: 18–20.
  11. Podchufarova E.V., Jahno N.N. Bol' v spine / M.: GEOTAR-Media, 2010; 368 s.
  12. Preobrazhenskij D.V., Sidorenko B.A., Tarykina E.V. i dr. Hronicheskaja serdechnaja nedostatochnost' u lits pozhilogo vozrasta: osobennosti etiopatogeneza i medikamentoznogo lechenija // Consilium Medicum. – 2005; 7 (12): 35–8.
  13. Sturov N.V., Kuznetsov V.I. Kliniko-farmakologicheskaja harakteristika NPVS dlja vracha obschej praktiki // Zemskij vrach. – 2011; 1: 11–4.
  14. Surskaja E.V. Sovremennye aspekty lechenija dorsopatii // Rus. med. zhurn. – 2010; 18: 58–61.
  15. Shostak N.A., Klimenko A.A. Nesteroidnye protivovospalitel'nye preparaty – sovremennye aspekty ih primenenija // Klinitsist. – 2013; 3–4: 53–61.
  16. Shostak N.A., Rjabkova A.A., Savel'ev V.S. i dr. Kliniko-instrumental'naja harakteristika zheludochno-kishechnyh krovotechenij, obuslovlennyh nesteroidnymi protivovospalitel'nymi preparatami // Eksper. i klin. gastroenterol. – 2003; 6: 91–4.
  17. Cryer B., Li C., Simon L. et al. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial // Am. J. Gastroenterol. – 2013; 108 (3): 392–400.
  18. Friedel H., Fitton A. Flupirtine: a review of its pharmacological properties, and therapeutic efficacy in pain states // Drugs. – 1993; 45 (4): 548–69.
  19. Jurna I., Nickel B., Lobisch M. Analgetisch und mioralaxierend: Flupirtine // Pharmazie. – 1992; 137 (35): 24–32.
  20. Herrmann W., Kern U., Aigner M. On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis // Postgrad. Med. J. – 1987; 63: 87–103.
  21. Herrmann W., Hiersemenzel R., Aigner M. et al. Long-term tolerability of Flupirtine // Fortschritte der Medizin. – 1993; 111 (15): 3–13.
  22. Kornhuber J., Bleich S., Wiltfang J. et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels // J. Neural. Transm. – 1999; 106 (9–10): 857–67.
  23. Larkai E., Smith J., Lidsky M. et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritis patients during chronic nonsteroidal anti-inflammatory drug use // Am. J. Gastroenterol. – 1987; 82 (11): 1153–8.
  24. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study // Fortschr. Med. Orig. – 2003; 121 (1): 11–8.
  25. Osborne N., Cazevieille C., Wood J. Flupirtine, a Nonopioid Centrally Acting Analgesic, Acts as an NMDA Antagonist // General Pharmacology. – 1998; 30 (3): 255–63.
  26. Roth S. Nonsteroidal anti-inflammatory drug gastropathy. We started it – can we stop it? // Arch. Intern. Med. – 1986; 146 (10): 1075–6.
  27. Roth S. NSAID gastropathy. A new understanding // Arch. Intern. Med. – 1996; 156 (15): 1623–8.
  28. Roth S., Bennett R. Nonsteroidal antiinflammatory drug gastropathy. Recognition and response // Arch. Intern. Med. – 1987; 147 (12): 2093–100.
  29. Schuster D., Schwarz M., Block M. et al. Flupirtine: a review of its neuroprotective and behavioral properties // CNS Drugs. – 1997; 12: 13–8.
  30. Sitzer G. Einfachblindstudie mit Flupirtine gagan Acetylsalicylsaure bei Patienten mit Spinalem Wurzelreizsyndrome // Orthop. Traumatol. – 1991; 6: 37–44.
  31. Weiser T., Szelenyi I., Nickel B. et al. In vitro and in vivo findings about the muscle relaxing properties of flupirine // Naunyn-Schmiedeberg's Arch. Pharmacol. – 1992; 246 (Supp. 1): R22.